EGFR and non-small cell lung carcinoma: Our hypotheses are as follows: The use of HAD B1 should improve the efficacy of afatinib in the treatment of EGFR-positive patients with locally advanced or metastatic NSCLC and should reduce the toxicity associated with afatinib.